Author:
Khotskaya Yekaterina B.,Holla Vijaykumar R.,Farago Anna F.,Mills Shaw Kenna R.,Meric-Bernstam Funda,Hong David S.
Funder
The Cancer Prevention and Research Institute of Texas
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
MD Anderson Cancer Center Support Grant
NCATS
Subject
Pharmacology (medical),Pharmacology
Reference97 articles.
1. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo;Arbitrario;Cancer Chemotherapy and Pharmacology,2010
2. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition;Ardini;Molecular Oncology,2014
3. Neurotrophin signaling: Many exciting surprises!;Arevalo;Cellular and Molecular Life Sciences,2006
4. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor;Arevalo;Molecular and Cellular Biology,2000
5. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer;Arkenau;Journal of Clinical Oncology,2015
Cited by
225 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献